Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinoma.

Summary: Advanced bladder cancer (urothelial carcinoma) has long been a difficult disease to treat, often coming with a poor outlook for patients. However, a new "power couple" in medicine is offering fresh hope. This review explores how combining two specific drugs—Pembrolizumab and Enfortumab Vedotin (EV)—creates a powerful synergy. While Pembrolizumab unmasks cancer cells so the immune system can fight them, EV acts like a guided missile delivering medication directly to the tumor. Together, they break down the cancer's defenses better than either drug could alone. This combination represents a significant "ray of light," promising better outcomes and giving patients a fighting chance against drug resistance.